Leading Role in Clinical Trial Positions Hershey Medical Center in Vanguard of Urological Care

Penn State Health Milton S. Hershey Medical Center is one of eight academic medical centers nationwide taking part in a clinical trial of Cxbladder — a noninvasive test that could spare thousands of patients the pain and expense involved in evaluating a diagnosis of hematuria.

Penn State Health Tests Novel, Nonsurgical Therapy for Common Form of Bladder Cancer

Patients with a noninvasive, low-grade form of bladder cancer often need multiple surgeries to treat recurrences, which are common. A new chemoablative gel currently under study at Penn State Health may eliminate the need for those procedures.

Penn State Health St. Joseph Cancer Center Brings Advanced Technology and High-Level Care to Berks County

The newly renovated Penn State Health St. Joseph Cancer Center in Bern Township delivers innovative oncology services and state-of-the-art technology to area patients so they can receive virtually the entire spectrum of cancer care without the burden of long commutes.

Expanded Clinical Trials at Penn State Cancer Institute Boost Area Patients’ Access to Leading-Edge Care

With a significant expansion of researcher-driven clinical trials and a sharp focus on the region’s distinct healthcare needs, Penn State Cancer Institute (PSCI) is bringing the latest in cancer treatments to central Pennsylvania.

Hershey Medical Center Achieves More Accurate Prostate Cancer Diagnosis with MRI-Guided Fusion Biopsy

Merging the capabilities of MRI and ultrasound technology in real time, Penn State Health Milton S. Hershey Medical Center uses MRI-guided fusion biopsy to more accurately detect the presence and aggressiveness of prostate cancer. This innovative technique facilitates accurate prostate cancer diagnosis while reducing the possibility of nondiagnostic biopsies and the need for repeat procedures.

Groundbreaking CAR-T Cell Therapy Arrives at Penn State Cancer Institute

Penn State Cancer Institute is the first and only healthcare facility in central Pennsylvania to offer the leading-edge treatment CAR-T cell (CAR-T) therapy to adult patients with lymphoma who have exhausted all other options. Kite Pharma, a division of Gilead, chose just a handful of U.S. facilities for its rollout of the potentially lifesaving treatment, Yescarta, which uses gene editing to boost patients’ own T cells against their cancer.

Setting the Standard for Exercise Oncology

Cancer treatment summons to mind images of patients passively undergoing chemotherapy or radiation treatment, not actively participating in a program of exercise to alleviate symptoms and enhance outcomes.

Liver Cancer Patients Have Local Access to Minimally Invasive, Life-Extending Treatment at Penn State Health St. Joseph Cancer Center

Penn State Health St. Joseph Cancer Center integrates tissue-sparing yttrium-90 selective internal radiation therapy (Y-90 SIRT) into treatment of liver cancer, offering many local patients improved outcomes over conventional treatments alone.

Leveraging Robotic Technology for Less-Invasive Treatment of HPV-Induced Oropharyngeal Cancer

Armed with the Flex Robotic System, experienced surgeons at Penn State Health Milton S. Hershey Medical Center can offer patients with human papillomavirus-induced head and neck cancers an advanced, local treatment option that is significantly less invasive than conventional open surgery.

Advanced Microsurgical Procedures at Milton S. Hershey Medical Center Offer Safer, More Natural Breast Reconstruction

Microsurgical flap procedures reconstruct breasts using patients’ own adipose tissue, creating a more natural appearance than saline or silicone implants. These procedures, which locally are performed only at Penn State Health Milton S. Hershey Medical Center, are also safer options for breast cancer patients who have undergone radiation therapy and mastectomy.